Search clinical trials for: with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies

Total 274 results

Chuncheon Sacred Heart Hospital

Completed

Immunological Measurement of Aspartate/Alanine Aminotransferase

Chronic Liver Disease and Cirrhosis
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer

Ovarian Cancer

United States
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Dragonboat Biopharmaceutical Company Limited
West China Hospital

Recruiting

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Fundacion GESICA
Merck Sharp & Dohme LLC

Recruiting

A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires

Flavivirus Infections | Dengue

Argentina
Changhai Hospital

Not yet recruiting

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody (PMMR/MSS)

Rectal Cancer
Memorial Sloan Kettering Cancer Center
Adaptive Biotechnologies

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
University of Mostar

Completed

Prognostic Value of Protein IMP3 Expression in Cervical Cancer

Cervical Carcinoma
University Medical Center Groningen

Completed

Using Vedolizumab-800CW to Gain Insight Into Local Drug Distribution and Mucosal Target Cells in IBD Patients (VISION)

Crohn Disease | Colitis, Ulcerative

Netherlands
Amgen

Completed

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Post-Menopausal Osteoporosis

United States, Poland, United Kingdom
Novartis Pharmaceuticals

Completed

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Multiple Sclerosis

United States, Austria, Spain, Czechia, Estonia, Bulgaria, Latvia, Lithuania, Russian Federation
Janssen Research & Development, LLC
GlaxoSmithKline

Completed

Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants

Healthy

United States
LiNing

Not yet recruiting

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Colorectal Neoplasms

China
Wake Forest University Health Sciences

Withdrawn

Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma

Amputation | Urologic Injuries | Genital Diseases, Male
Memorial Sloan Kettering Cancer Center

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Neuroblastoma

United States
LEO Pharma

Completed

A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

Colorectal Cancer
Maximilian Diehn
Varian Medical Systems

Completed

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
Philogen S.p.A.

Terminated

Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients

Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection

Italy, Germany
Lee's Pharmaceutical Limited

Recruiting

Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
University of Virginia
National Cancer Institute (NCI)

Terminated

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Genmab

Completed

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Cancer

Sweden, United Kingdom, France, Hungary, Canada, Brazil, Belgium, Lithuania, Russian Federation, Serbia, Estonia, Poland
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Shandong Cancer Hospital and Institute

Recruiting

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Breast Cancer | Small Cell Lung Cancer | Colorectal Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Squamous Cell Cancer of Head and Neck

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
MedImmune LLC

Completed

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Advanced Solid Tumors

United States, Australia
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
Northwestern University
National Cancer Institute (NCI); Celgene; The Leukemia and Lymphoma Society

Withdrawn

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Microsatellite Instability | Hormone-Resistant Prostate Cancer | Castration Levels of Testosterone

United States
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell Carcinoma

United States
Alain Algazi
AstraZeneca; Incyte Corporation

Withdrawn

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Epstein-Barr Virus Positive | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma
Bradmer Pharmaceuticals Inc.

Unknown

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Brain Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Human Papillomavirus Infection | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal... and other conditions

United States
Centre Leon Berard

Completed

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE)

Squamous Cell Carcinoma of the Head and Neck

France
Thomas Jefferson University
Janssen Scientific Affairs, LLC

Active, not recruiting

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8

United States
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
AstraZeneca

Recruiting

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer

Spain, United States, Belgium, United Kingdom, France, Hungary, Canada, Korea, Republic of, Australia
Pfizer

Terminated

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Non-small Cell Lung Cancer | Urothelial Cancer

Spain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
Amsterdam UMC, location VUmc
Radboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaborators

Active, not recruiting

Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

Myeloma

Netherlands
John Reneau

Active, not recruiting

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditions

United States
University of Nebraska
AstraZeneca

Terminated

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
Roswell Park Cancer Institute
GlaxoSmithKline

Active, not recruiting

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States

Search clinical trials for: with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations